Syncona

Syncona is a London-listed investment company focused exclusively on the life sciences sector, structured as a permanently capitalised investment trust listed on the London Stock Exchange, which allows it to take very long-term positions in clinical-stage biopharmaceutical companies without the fund lifecycle constraints of conventional venture capital. The company creates and builds life science companies in partnership with world-leading academic scientists from institutions including the Francis Crick Institute and University College London. Portfolio companies include Autolus Therapeutics, the clinical-stage T cell therapy company that completed a Nasdaq IPO in 2018; Blue Earth Diagnostics, the molecular imaging company acquired by Lantheus Holdings; OMass Therapeutics, the Oxford University spinout developing medicines targeting membrane proteins; and Freeline Therapeutics, the gene therapy company. Beyond its original investments, the portfolio includes additional UK clinical-stage life science companies.